In places with low vaccination rates, COVID-19 has the chance to linger, and variants develop and travel. Without global vaccine equity, this entirely predictable pattern will repeat itself.
The fight for vaccine equity needs to stop looking to multilateral institutions for permission and instead focus on the policy tools that are already available to states.
African governments, firms and donor agencies should align their efforts to support the local manufacture of vaccines and other health equipment in African countries.
There are three broad sets of health-related opportunities and benefits that may shape the future of India-Africa relations.
Italy’s decision to block export of AstraZeneca vaccines to Australia will likely not impact our vaccine roll-out. But vaccine scarcity is a looming problem in other parts of the world.
Governments are naturally under pressure to focus on national rollouts. But the truth is none of us is safe until we’re all safe.
Vaccines should be seen as a kind of foreign aid.
With $1 billion in advance purchase agreements for COVID-19 vaccines, Canada has joined the vaccine nationalists: rich countries buying up more than half the global short-term supply of vaccine.
More than 170 countries have signed up to the Global Access (COVAX) initiative, but vaccine hoarding has already begun by many wealthy countries — leaving poorer nations potentially in the lurch.
A two-dose coronavirus vaccine would mean we need to produce 12-15 billion doses. This is roughly twice the world’s current total vaccine manufacturing capacity.
Instead of a global response to the pandemic, we’re seeing an outbreak of vaccine nationalism.
Should the US be able to pre-order vaccines for its citizens when other populations around the globe are at greater risk?